Price (delayed)
$13.7
Market cap
$1.77B
P/E Ratio
28.54
Dividend/share
N/A
EPS
$0.48
Enterprise value
$1.87B
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of
There are no recent dividends present for DVAX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.